A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Recurrent Ovarian Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Dec 2016
At a glance
- Drugs Acalabrutinib (Primary) ; Pembrolizumab
- Indications Ovarian cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms KEYNOTE191
- Sponsors Acerta Pharma
- 27 Jun 2016 Planned End Date changed from 1 Aug 2018 to 1 Jul 2018.
- 12 Nov 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 04 Sep 2015 New trial record